Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators ... is based on research showing the medicine, called inavolisib, could offer a ...

Roche Holding said the U.S. Food and Drug Administration granted priority review to the company's new drug application for inavolisib as a treatment for a type of advanced breast cancer.

Roche RHHBY announced that the FDA has approved pipeline candidate, inavolisib, for the treatment of breast cancer ... based regimen was granted Priority Review by the FDA. It was also granted ...

Roche's Itovebi was the first PI3K inhibitor to get approved ... has an FDA green light as part of a combination regimen for patients with advanced HR-positive, HER2-negative breast cancer with ...

Two promising candidates in Roche’s breast cancer pipeline are giredestrant and inavolisib, among others. Inavolisib is currently under review in ... recently won FDA approval for Kisqali ...

Roche and Lilly said they believe the test could play an important role in improving access to early and accurate Alzheimer’s diagnosis. There are currently no FDA authorized blood tests for ...

The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant metastatic breast cancer. Among patients with liver-dominant metastatic ...

Roche and Lilly said they believe the test could play an important role in improving access to early and accurate Alzheimer’s diagnosis. There are currently no FDA authorized blood tests for ...